NCT04391179View on ClinicalTrials.gov

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

May 31, 2020

Primary Completion Date

February 22, 2021

Study Completion Date

February 22, 2021

Conditions
COVIDCorona Virus InfectionCovid-19SARS-CoV-2 Infection
Interventions
DRUG

Dipyridamole 100 Milligram(mg)

Drug will be given for 14 days while in the hospital.

DRUG

Placebo oral tablet

Placebo will be given for 14 days while in the hospital.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT04391179 - Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | Biotech Hunter | Biotech Hunter